Voydeya approved in the EU as add-on treatment to ravulizumab

ALPHA Phase III trial showed first-in-class, oral, Factor D inhibitor as add-on to Ultomiris or Soliris improved haemoglobin levels and reduced anaemia and fatigue

Sentynl Therapeutics receives marketing authorization for Nulibry from UK MHRA

NULIBRY is a first-in-class synthetic cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A

Akums launches Bharosa campaign

The campaign marks an important milestone in its journey within the pharmaceutical manufacturing industry

Mac-Chem Products (India)’s Boisar facility renews EU-GMP certification

Roche gets FDA approval for Alecensa in early lung cancer

This approval helps address an urgent unmet need, with about half of people living with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy

AIC-CCMB signs agreement for placement of equipment with Thermo Fisher Scientific to help advance innovation in India

Thermo Fisher has equipped this Centre for Innovation with state-of-the-art platforms such as CellInsight CX7 LZR Pro High Content Screening Platform

PharmaLytica 2024 to draw 200+ exhibitors

10th edition of the event is scheduled to be held during May 30-June 1 at Hitex, Hyderabad

Biocon inks agreement for Ozempic commercialization in Brazil with Biomm

Biocon will undertake the development, manufacturing and supply of the drug product, and Biomm will be responsible for obtaining regulatory approval and commercialization in the Brazilian market

USFDA grants ODD to NM5072 for treatment of Paroxysmal Nocturnal Hemoglobinuria

NM5072 is an anti-Properdin antibody that selectively blocks the alternative pathway while maintaining the integrity of the classical pathway required for fending off infections

AstraZeneca’s Imfinzi plus chemotherapy doubled overall survival rate for patients with advanced biliary tract cancer

Longest survival follow-up ever reported for immunotherapy treatment in this setting